Aenova will install an additional filling and manufacturing line at the Latina, Italy, site. This expansion is an important step to meet the increasing global demand for the production of biologics.
Fujifilm Biotechnologies has opened one of North America's largest commercial-scale cell culture biomanufacturing sites in Holly Springs, North Carolina, US.
Symeres has appointed Gabriella Gentile as Chief Operating Officer to lead global operations and drive transatlantic growth, leveraging her extensive experience in the pharmaceutical and biotech sectors.
Dinamiqs, a Siegfried company specialized in viral vector design and manufacturing, inaugurated its new cGMP manufacturing facility.
CRDMO Symeres has acquired DGr Pharma, expanding its capabilities with DGr Pharma’s regulatory and consultancy expertise to provide more comprehensive drug development services.
Bionova Scientific has opened a 10,000 square-foot state-of-the-art plasmid DNA (pDNA) development and production facility in The Woodlands, Texas.
Heino Lennartz will take over the role on an interim basis until Verheyden takes office in fall 2025.
Ofichem, a European CDMO specialising in high-quality active pharmaceutical ingredients (APIs) and integrated drug development and manufacturing services, has acquired Meribel Pharma Solutions’ site in Uppsala, Sweden.
Abzena, an end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, recently announced that Geoffrey M. Glass has been appointed Chief Executive Officer, effective immediately.
Sanner, a provider of high-quality healthcare packaging and drug delivery solutions, officially opened its first US-based production facility in Greensboro, North Carolina.
The pharmaceutical service provider Siegfried has announced changes to its management team. Marianne Späne, who has been with the Swiss CDMO since 2004 and has held the position of Chief Business Officer since the beginning of 2020, is moving to the Board of Directors of the subsidiary Dinamiqs.
The Flamma Group, a Contract Development and Manufacturing Organization (CDMO), recently celebrated the grand opening of a new cGMP plant in Dalian, China.
GenSight Biologics recently announced the successful transfer of the upstream phase of the manufacturing process for LUMEVOQ, the Company’s gene therapy candidate product to CDMO Catalent.
Aenova is investing in a new cold storage infrastructure at its sterile site in Latina (Italy), offering an end-to-end supply chain solution for biologics and other pharmaceutical products.
Mabion, a biotech-focused CDMO offering end-to-end services, has announced the launch of a €500,000 oncology services contest at BIO International Convention 2025.
Resilience recently shared that capacity expansions have exceeded current industry demand. As a result, Resilience has begun consolidating its operations and streamlining its business strategy.
Sterling Pharma Solutions to produce an antibody-drug conjugate (ADC) candidate for Kivu Bioscience.
Fujifilm Irvine Scientific becomes Fujifilm Biosciences, and Fujifilm Diosynth Biotechnologies will be known as Fujifilm Biotechnologies.
Curia, a CDMO, recently shared expansion plans for facilities in Glasgow, UK, and Albuquerque, NM, US.
Siegfried announced a further expansion of its ophthalmic drug manufacturing site in El Masnou near Barcelona, Spain.
Leading the Way in Pharmaceutical Manufacturing by Fostering an Agile Mindset and an Inclusive Culture.
Exclusive licensing and R&D collaboration between Hovione and Firstgene.
Aenova announces the launch of its Aenovation program. This initiative aims to accelerate the early development of pharmaceutical formulations.
Bionova Scientific, an Asahi Kasei boutique commercial-scale biologics contract development and manufacturing organization (CDMO), has licensed ATUM’s proprietary Leap-In Transposase transposon-based gene delivery and its miCHO cell line development technologies.
PCI Pharma Services has completed its acquisition of Ajinomoto Althea, a CDMO subsidiary of Ajinomoto.
Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing supply agreement, valued at over $3 billion (€2.64 billion), with Regeneron Pharmaceuticals to provide US-based production of its industry-leading biologic medicines, which treat millions of patients worldwide.
CDMO Suanfarma appoints Pere Mañé Godina as its new CEO, marking the beginning of a new chapter for the company, focused on industrial consolidation, sustainable innovation, and global expansion.
A new, mid-size Contract Development Manufacturing Organisation (CDMO), Meribel Pharma Solutions, has launched today with an extensive integrated network across Europe.
HAS Healthcare Advanced Synthesis (HAS) recently announced the planned acquisition of Cerbios-Pharma (Cerbios), a globally recognized manufacturer of chemical and biological APIs, including antibody-drug conjugates (ADCs).
Syngene, a global contract research, development, and manufacturing organization (CRDMO), recently announced the acquisition of its first biologics site in the USA – fitted with multiple monoclonal antibody (mAbs) manufacturing lines.
Axplora, an API small molecule and ADC (antibody-drug conjugate) manufacturer, is strengthening its position in the commercial manufacturing ADCs by launching a cutting-edge payload manufacturing workshop at its Le Mans site (France).
German contract development and manufacturing organization (CDMO) Adragos Pharma has completed a €4 million project to install and commission a new, cGMP-compliant liquid drug filling line and associated cartoning machine at its plant in Leipzig, Germany.
Contract development and manufacturing organization (CDMO) CordenPharma has finalized plans to establish a new peptide manufacturing facility in Switzerland located at Getec Park in Muttenz near Basel. This investment is part of the company’s growth initiatives with a more than €1 billion strategic investment in peptide development and manufacturing.
Indian pharmaceutical company Granules India has agreed to acquire Senn Chemicals, a Swiss-based contract development and manufacturing organization (CDMO) specializing in peptides. The closing of the deal, which is subject to certain conditions, is expected to occur in the first half of 2025. Financial details of the transaction were not disclosed.
Jabil, a global provider of engineering, manufacturing, and supply chain solutions, has acquired Pharmaceutics International (Pii), a US contract development and manufacturing organization (CDMO) specializing in early-stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing. Financial details of the transaction, which was completed on Feb. 3, 2025, were not given.
